Guangzhou Baiyunshan Pharmaceutical Holdings (00874): The Guangdong Provincial Drug Administration approved the reduction of production lines at Hejigong Pharmaceutical Factory.

Guangzhou Baiyunshan Pharmaceutical Holdings (00874) announced that its subsidiary Guangzhou Baiyunshan Pharmaceutical Holdings Medical Group Co., Ltd. (hereinafter referred to as the "Company") has received a "Drug Production License" issued by the Guangdong Food and Drug Administration, approving the reduction of production lines at the Hejigong Pharmaceutical Factory of Guangzhou Baiyunshan Pharmaceutical Holdings. The approval allows the Hejigong Pharmaceutical Factory to reduce the production line at the "Xingzhou Manufacturing Department" in the production workshop located at "No.4, South Chuangye Avenue, Mingzhu Industrial Park, Conghua District, Guangzhou (excluding Building K1)." The production scope of the F building production line is in the Chinese medicine pre-treatment and extraction workshop. The reason for the reduction of this production line is part of the production capacity adjustment of the Hejigong Pharmaceutical Factory, which is beneficial for optimizing the company's resource allocation, maintaining stable production capacity, and meeting market demand. The acquisition of the "Drug Production License" in this instance has no significant impact on the company's current performance.